MetaCap

Compass Therapeutics (CMPX) vs Protara Therapeutics (TARA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Protara Therapeutics (TARA) has outperformed Compass Therapeutics (CMPX) over the past year, losing 68.6% versus a loss of 85.9%. Over five years, TARA leads with a -67.8% price change compared with -78.6% for CMPX. Protara Therapeutics is the larger company by market cap ($140.4 million vs $123.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CMPX-85.87%TARA-68.60%
+44%-25%-94%
Nov 21, 20251 yearNov 20, 2026
CMPX-80.22%TARA-68.33%
+96%+2%-93%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CMPX versus TARA key metrics
MetricCMPXTARA
Share price$0.6882$2.28
Market cap$123.94M$140.38M
1-day change+1.43%-5.00%
YTD return-87.18%-57.22%
1-year return-85.87%-68.60%
5-year return-78.63%-67.80%
EPS (TTM)$-0.46$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-66.49M$-57.44M
52-week high$6.88$7.82
52-week low$0.57$2.09
Distance from 52-week high-90.00%-70.84%
Analyst consensusbuystrong_buy
Avg. price target upside+664.31%+1010.96%
Average volume3.88M1.07M
Shares outstanding180.09M61.57M
Employees3946
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TARA has outperformed CMPX by 17.3 percentage points over the past year.

About Compass Therapeutics

CMPX stock →

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees

About Protara Therapeutics

TARA stock →

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

CMPX vs TARA FAQ

Which is bigger, Compass Therapeutics or Protara Therapeutics?

Protara Therapeutics (TARA) is larger, with a market capitalization of $140.38M compared with $123.94M for Compass Therapeutics (CMPX).

Which stock has performed better over the past year, CMPX or TARA?

TARA returned -68.60% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.

Are Compass Therapeutics and Protara Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons